VectorY Appoints Khurem Farooq to Board of Directors
VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, today announced the appointment of industry veteran Khurem Farooq as independent board member, effective immediately.
- VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, today announced the appointment of industry veteran Khurem Farooq as independent board member, effective immediately.
- Khurem Farooq is an accomplished industry leader who brings more than 20 years of operational and drug development experience.
- He currently serves as the CEO at Aiolos Bio which recently announced an agreement to be acquired by GSK.
- Sander van Deventer, CEO of VectorY, commented: “We are delighted to welcome Khurem to VectorY as an independent board member.